Exercise on microRNA in Osteoarthritis

NCT05869630 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-06-06

No results posted yet for this study

Summary

The present study is a prospective cohort study. This study will be conducted to determine the change in miRNA levels with exercise in knee Osteoarthritis (OA) patients. The main questions that the study aims to answer are:

Question 1: Does exercise therapy affect microrna expressions in patients with knee osteoarthritis?

Question 2: Does exercise therapy affect quality of life, pain, functional status and depression level in patients with knee osteoarthritis?

Participants; demographic information such as age, height, weight will be questioned. Exercises will performed twice a week under supervision and once a week as home program for eight weeks. Before and after exercise treatment, peripheral venous blood samples will taken from both groups. miRNA-146a, miRNA-155, miRNA-221-3p and miRNA-145 gene expressions will studied with the real-time PCR (polymerase chain reaction) method. miRNA-146a, miRNA-155, and miRNA-221-3p, miRNA-145 gene expressions will studied with the Real-time PCR method. The pain will evaluated with the Numeric Rating Scale (NRS), functional status with Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), depression level with the Beck Depression Inventory (BDI), and quality of life with Short Form-36 (SF-36).

Conditions

  • Osteoarthritis, Knee
  • Epigenetic Disorder
  • Quality of Life
  • Depression
  • Pain

Interventions

OTHER

Exercise Programme

All patients were informed about knee OA, joint protection principles, and the exercise effects on knee OA before treatment. The exercises were supervised by a physiotherapist for 30 minutes twice a week and once a week as a home program. The exercise program consisted of a warm-up, strengthening knee extensors and lower extremity stretching exercises. Firstly, quadriceps isometric and adductor isometric (roll tightening) exercises, hamstring stretching, quadriceps stretching, and gastrocnemius stretching were applied. Then, hip flexion-extension-abduction-adduction, and knee extension while sitting were applied with exercise bands. Strengthening exercises were composed of three sets with 10 repetitions. Stretching exercises were performed 10 repetitions for 10 seconds.

OTHER

Experiments

The total RNA was isolated from peripheral blood samples taken from patients and the control group by applying the protocol of the manufacturer (LucigenMasterPure™ Complete DNA and RNA Purification Kit, USA). The total RNA was isolated in three steps: Lysis stage of the whole blood samples, precipitation of nucleic acids and precipitation of total RNA. The purity and concentration of the isolated total RNA samples were measured with the spectrophotometer (Thermo Fischer) device. The samples were stored at -80°C until the next step. To determine the microRNA expression levels; firstly, conjugate DNA (cDNA) was synthesized from total RNA samples according to the manufacturer's protocol. Whether the desired region reproduced in the reaction and whether there were primer dimers were checked by adding a melting curve step. In addition, blood samples of 30 age-sex matched healthy volunteers were compared.

Sponsors & Collaborators

  • Saglik Bilimleri Universitesi

    lead OTHER

Principal Investigators

  • Fulya Senem KARAAHMETOĞLU, M.Sc · Saglik Bilimleri Universitesi

  • Zeynep Betül ÖZCAN, M.Sc · Saglik Bilimleri Universitesi

  • Meltem VURAL, Prof. Dr. · Istanbul Bakırköy Dr.Sadi Konuk Training and Research Hospita

  • Işıl ÜSTÜN, Dr. · Istanbul Bakırköy Dr.Sadi Konuk Training and Research Hospita

  • Alev KURAL, Prof. Dr. · Istanbul Bakırköy Dr.Sadi Konuk Training and Research Hospita

  • Sibel KURAŞ, M. Sc. · Saglik Bilimleri Universitesi

  • Bekir ERDOĞAN, M.Sc · Saglik Bilimleri Universitesi

  • Halime Hanım PENÇE, Assoc. Prof. · Saglik Bilimleri Universitesi

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
38 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2019-09-11
Completion
2020-06-17

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05869630 on ClinicalTrials.gov